January 6, 2017 / 12:07 PM / 7 months ago

BRIEF-Contrafect provides program update

Jan 6 (Reuters) - Contrafect Corp

* Contrafect provides program update

* Now expects to initiate phase 2 study of CF-301 in patients with staphylococcus aureus bacteremia in mid-2017

* In relation to phase 2 study of CF-301, an investigational drug product lot did not meet manufacturing release specifications Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below